PureTech Health : INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K - Form 6-K

6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of November, 2023

Commission File Number 001-39670

PURETECH HEALTH PLC

(Translation of registrant's name into English)

6 Tide Street, Suite 400

Boston, Massachusetts 02210

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On May 9, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the "Company") announced the commencement of a $50 million share repurchase program (the "Program") of its ordinary shares of one pence each ("Ordinary Shares"). The Company plans to execute the Program in two equal tranches, the first of which was completed on October 26, 2022. In respect of each of the two tranches, PureTech entered into an irrevocable non-discretionary instruction with Jefferies International Limited ("Jefferies") in relation to the purchase by Jefferies of Ordinary Shares for an aggregate consideration (excluding expenses) of no greater than $25 million and the simultaneous on-sale of such Ordinary Shares by Jefferies to PureTech. Jefferies makes its trading decisions in relation to the Ordinary Shares independently of, and uninfluenced by, the Company. Purchases may continue during any close period to which the Company is subject. Any purchase of Ordinary Shares under the second tranche of the Program are carried out on the London Stock Exchange and any other UK recognized investment exchange which may be agreed, in accordance with pre-set parameters and in accordance with, and subject to limits, including those limits related to daily volume and price, prescribed by the Company's general authority to repurchase Ordinary Shares granted by its shareholders at its most recent annual general meeting on June 13, 2023, Chapter 12 of the Financial Conduct Authority's UK Listing Rules, Article 5(1) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and Commission Delegated Regulation (EU) 2016/1052 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018). All Ordinary Shares repurchased under the Program will be held in treasury.

During the month ended November 30, 2023, the Company had the following daily purchases of its own Ordinary Shares under the Program through Jefferies:

Date

Ordinary Shares Repurchased

Volume Weighted Average Price Paid per Ordinary Share

Highest Price Paid

Lowest Price Paid

November 1, 2023

47,566

150.30p

154.80p

149.00p

November 2, 2023

35,710

157.86p

161.40p

154.60p

November 3, 2023

38,688

158.90p

161.60p

154.00p

November 6, 2023

40,474

162.31p

162.80p

161.40p

November 7, 2023

24,745

160.94p

163.00p

159.00p

November 8, 2023

44,412

163.97p

165.60p

160.40p

November 9, 2023

1,835

168.60p

168.60p

168.60p

November 10, 2023

42,611

164.81p

171.40p

162.80p

November 13, 2023

44,425

170.44p

171.60p

164.00p

November 14, 2023

2,116

173.39p

174.00p

173.20p

November 16, 2023

25,140

179.00p

182.20p

176.80p

November 17, 2023

44,415

176.95p

181.00p

170.60p

November 20, 2023

50,034

172.77p

174.60p

171.40p

November 21, 2023

52,644

165.60p

172.00p

163.40p

November 22, 2023

49,514

166.60p

169.00p

164.40p

November 23, 2023

48,600

164.25p

166.20p

161.00p

November 24, 2023

32,582

163.39p

165.20p

162.20p

November 27, 2023

37,169

162.84p

164.80p

160.40p

November 28, 2023

39,084

157.74p

160.20p

156.20p

November 29, 2023

35,923

157.58p

160.80p

156.60p

November 30, 2023

50,660

154.99p

157.80p

152.20p

During the month ended November 30, 2023, the Company repurchased an aggregate of 788,347 Ordinary Shares. As of November 30, 2023, the Company's issued share capital was 289,468,159 shares, 16,751,624 of which were held in treasury, resulting in total voting rights in the Company of 272,716,535 shares. To view the details of the individual transactions, please paste the following URL(s) into the address bar of your browser with respect to each individual date of repurchase under the Program:

November 1, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4956432.html

November 2, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4957868.html

November 3, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4959395.html

November 6, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4960859.html

November 7, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4962367.html

November 8, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4963913.html

November 9, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4965428.html

November 10, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4966863.html

November 13, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4968374.html

November 14, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4969850.html

November 16, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4972892.html

November 17, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4974299.html

November 20, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4975816.html

November 21, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4977290.html

November 22, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4979125.html

November 23, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4980541.html

November 24, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4981979.html

November 27, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4983534.html

November 28, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4984991.html

November 29, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4986623.html

November 30, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4988247.html

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		PURETECH HEALTH PLC
Date: December 5, 2023			By:		/s/ Daphne Zohar
			Name: Daphne Zohar
			Title: Chief Executive Officer